Multiple Sclerosis
Conference Recap
Multiple sclerosis updates from AAN 2021
Mitzi Joi Williams, MD, highlights important updates in multiple sclerosis stemming from the American...
Conference Coverage
Investigational drug reduces brain lesions in highly active MS
Tolebrutinib, a BTK inhibitor, reduced new gadolinium-enhancing lesions and new and enlarging T2 lesions.
Conference Coverage
Some MS treatments may heighten COVID risk
An Italian registry shows worse outcomes with anti-CD20 treatment, but a possible protective effect of interferon and teriflunomide.
Conference Coverage
Evobrutinib may lower nerve damage biomarker levels
A post hoc analysis reports the Bruton’s tyrosine kinase inhibitor evobrutinib lowered neurofilament light chain blood levels in multiple...
Conference Coverage
Common MS treatment wears off more quickly in Black patients
These findings may have implications for the way Black patients with autoimmune diseases are treated in the future.
Supplements
Highlights from ACTRIMS/ECTRIMS
Conference Recap
ACTRIMS 2021: Safety and efficacy of disease-modifying therapies in multiple sclerosis
Mark S. Freedman, MSc, MD, summarizes abstracts on DMTs that were presented at the ACTRIMS Forum...
Conference Recap
Updates in multiple sclerosis symptom management from ACTRIMS 2021
Joseph R. Berger, MD, summarizes abstracts in MS symptom management that were presented at the...
Conference Coverage
Can supplementary estrogen relieve MS symptoms in menopausal women?
Research suggests lowered hormone levels may worsen the disease.
Literature Review
Neurologic drug prices jump 50% in five years
Most of the increased cost was due to rising costs for neuroimmunology drugs, mainly for those used to treat multiple sclerosis (MS).